KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma

Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non‐small‐cell lung carcinoma (NSCLC) with aggressive behaviour. This study aimed to evaluate the prognostic clinicopathological and genetic characteristics of PSCs.

[1]  P. Stephens,et al.  Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  A. Bankier,et al.  Measurement Bias of Gross Pathologic Compared With Radiologic Tumor Size of Resected Lung Adenocarcinomas: Implications for the T-Stage Revisions in the Eighth Edition of the American Joint Committee on Cancer Staging Manual , 2017, American journal of clinical pathology.

[3]  S. Dacic,et al.  ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma , 2016, Oncotarget.

[4]  Yufeng Shen,et al.  Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Mazières,et al.  Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. , 2016, Clinical lung cancer.

[6]  P. Stephens,et al.  Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  G. Rossi,et al.  Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  J. Jen,et al.  Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases , 2016, Modern Pathology.

[9]  J. Davison,et al.  Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging , 2016, Modern Pathology.

[10]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[11]  P. Jänne,et al.  MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Frampton,et al.  MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Gonçalo R. Abecasis,et al.  Unified representation of genetic variants , 2015, Bioinform..

[14]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[15]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[16]  N. Girard,et al.  High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Jin-An Ma,et al.  Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: A case report. , 2015, Oncology letters.

[18]  M. Ladanyi,et al.  Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Vincent A. Fusaro,et al.  A Python package for parsing, validating, mapping and formatting sequence variants using HGVS nomenclature , 2014, Bioinform..

[20]  M. Antoine,et al.  Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. , 2014, Lung cancer.

[21]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[22]  L. Pantanowitz,et al.  Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas. , 2014, American journal of clinical pathology.

[23]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Simion I. Chiosea,et al.  The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma , 2013, Cancer.

[25]  M. Ladanyi,et al.  Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas , 2013, Cancer.

[26]  Austin Miller,et al.  Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. , 2012, Surgery.

[27]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[28]  Yih-Leong Chang,et al.  EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy , 2011, Annals of Surgical Oncology.

[29]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[30]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[31]  A. Italiano,et al.  EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti‐EGFR treatment of a rare lung malignancy , 2009, International journal of cancer.

[32]  K. Kubo,et al.  Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. , 2009, Japanese journal of clinical oncology.

[33]  L. Seymour,et al.  Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[35]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[36]  W. Travis.  WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .

[37]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.